Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 1577.7 mg (equivalent: cefuroxime, qty 1500 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - cefuroxime sodium, quantity: 788.9 mg (equivalent: cefuroxime, qty 750 mg) - injection, powder for - excipient ingredients: - cefuroxime sxp is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime sxp is not indicated in children less than 40 kg in weight.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 300.715 mg - tablet, film coated - excipient ingredients: crospovidone; calcium carbonate; microcrystalline cellulose; calcium stearate; croscarmellose sodium; purified water; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 601.43 mg - tablet, film coated - excipient ingredients: crospovidone; calcium stearate; purified water; colloidal anhydrous silica; calcium carbonate; microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 300.715 mg - tablet, film coated - excipient ingredients: crospovidone; croscarmellose sodium; calcium carbonate; calcium stearate; purified water; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 601.43 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; calcium stearate; microcrystalline cellulose; sodium lauryl sulfate; purified water; calcium carbonate; croscarmellose sodium; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg in 5 ml - note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well-controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen. - pharyngitis/tonsillitis caused by streptococcus pyogenes. note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil for oral suspensio

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime  

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticali inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - cefuroxime axetil tablets usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets usp are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non- β-lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil tablets usp for sinus infections caused by β-la

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non-β-lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil for sinus infections caused by β-lactamase–producing haemoph